Multidimensional Protein Solubility Optimization with an Ultrahigh-Throughput Microfluidic Platform
Open Access
- 17 March 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 95 (12) , 5362-5368
Abstract
Protein-based biologics are highly suitable for drug development as they exhibit low toxicity and high specificity for their targets. However, for therapeutic applications, biologics must often be formulated to elevated concentrations, making insufficient solubility a critical bottleneck in the drug development pipeline. Here, we report an ultrahigh-throughput microfluidic platform for protein solubility screening. In comparison with previous methods, this microfluidic platform can make, incubate, and measure samples in a few minutes, uses just 20 μg of protein (>10-fold improvement), and yields 10,000 data points (1000-fold improvement). This allows quantitative comparison of formulation excipients, such as sodium chloride, polysorbate, histidine, arginine, and sucrose. Additionally, we can measure how solubility is affected by the combinatorial effect of multiple additives, find a suitable pH for the formulation, and measure the impact of mutations on solubility, thus enabling the screening of large libraries. By reducing material and time costs, this approach makes detailed multidimensional solubility optimization experiments possible, streamlining drug development and increasing our understanding of biotherapeutic solubility and the effects of excipients.Keywords
Funding Information
- AstraZeneca
- Royal Society (URFR1201461)
- Novo Nordisk
- University of Cambridge
- European Commission (101023060)
- University of Cambridge
- Wellcome Trust (203249/Z/16/Z)
- China Scholarship Council
- Frances and Augustus Newman Foundation
- European Commission (337969)
This publication has 37 references indexed in Scilit:
- Engineering Aggregation-Resistant AntibodiesAnnual Review of Chemical and Biomolecular Engineering, 2012
- Preparation of size-controlled bovine serum albumin (BSA) nanoparticles by a modified desolvation methodFood Chemistry, 2011
- Aggregates in monoclonal antibody manufacturing processesBiotechnology and Bioengineering, 2011
- Application of a High-Throughput Screening Procedure with PEG-Induced Precipitation to Compare Relative Protein Solubility During Formulation Development with IgG1 Monoclonal AntibodiesJournal of Pharmaceutical Sciences, 2011
- Development trends for human monoclonal antibody therapeuticsNature Reviews Drug Discovery, 2010
- Aggregation-Prone Motifs in Human Immunoglobulin GJournal of Molecular Biology, 2009
- Life on the edge: a link between gene expression levels and aggregation rates of human proteinsTrends in Biochemical Sciences, 2007
- A Microfluidic Device for Kinetic Optimization of Protein Crystallization and In Situ Structure DeterminationJournal of the American Chemical Society, 2006
- Challenges in the development of high protein concentration formulationsJournal of Pharmaceutical Sciences, 2004
- Screening of Protein Crystallization Conditions on a Microfluidic Chip Using Nanoliter-Size DropletsJournal of the American Chemical Society, 2003